Page 33 - Glucose Monitoring Devices

28 CHAPTER 1 Introduction to SMBG

[88] Allen B, DeLong E, Feussner J. Impact of glucose self-monitoring on non-insulin-
treated patients with type II diabetes mellitus: randomized controlled trial comparing
blood and urine testing. Diabetes Care 1990;13:1044e50. https://doi.org/10.2337/
diacare.13.10.1044.
[89] Zhu H, Zhu Y, Leung S. Is self-monitoring of blood glucose effective in improving gly-
caemic control in type 2 diabetes without insulin treatment: a meta-analysis of rando-
mised controlled trials. British Medical Journal Open 2016;6:e010524. https://doi.org/
10.1136/bmjopen-2015-010524.
[90] Mannucci E, Antenore A, Giorgino F, Scavini M. Effects of structured versus unstruc-
tured self-monitoring of blood glucose on glucose control in patients with non-insulin-
treated type 2 diabetes: a meta-analysis of randomized controlled trials. Journal of Dia-
betes Science and Technology 2017;12:183e9. https://doi.org/10.1177/
1932296817719290.
[91] Machry R, Rados D, Grego ´rio G, Rodrigues T. Self-monitoring blood glucose im-
proves glycemic control in type 2 diabetes without intensive treatment: a systematic
review and meta-analysis. Diabetes Research and Clinical Practice 2018;142:
173e87. https://doi.org/10.1016/j.diabres.2018.05.037.
[92] 7. Diabetes technology: standards of medical care in diabetesd2019. Diabetes Care
2018;42:S71e80. https://doi.org/10.2337/dc19-s007.
[93] DiMeglio L, Acerini C, Codner E, Craig M, Hofer S, Pillay K, et al. ISPAD Clinical
Practice Consensus Guidelines 2018: glycemic control targets and glucose monitoring
for children, adolescents, and young adults with diabetes. Pediatric Diabetes 2018;19:
105e14. https://doi.org/10.1111/pedi.12737.
[94] 14. Management of diabetes in pregnancy: standards of medical care in
diabetesd2019. Diabetes Care 2018;42:S165e72. https://doi.org/10.2337/dc19-s014.
[95] Recommendations j Diabetes in pregnancy: management from preconception to the
postnatal period j Guidance. NICE, Nice.Org.Uk; 2015. Available from: https://
www.nice.org.uk/guidance/ng3/chapter/1-Recommendations. [Accessed 1 June 2019].
[96] Bailey T, Grunberger G, Bode B, Handelsman Y, Hirsch I, Jovanovi c L, et al. Amer-
ican association of clinical endocrinologists and American college of endocrinology
2016 outpatient glucose monitoring consensus statement. Endocrine Practice 2016;
22:231e61. https://doi.org/10.4158/ep151124.cs.
[97] Rosenstock J, Davies M, Home P, Larsen J, Koenen C, Schernthaner G. A randomised,
52-week, treat-to-target trial comparing insulin detemir with insulin glargine when
administered as add-on to glucose-lowering drugs in insulin-naive people with type 2
diabetes. Diabetologia 2008;51:408e16. https://doi.org/10.1007/s00125-007-0911-x.
[98] Rationale, design, and baseline characteristics for a large international trial of cardio-
vascular disease prevention in people with dysglycemia: the ORIGIN Trial (outcome
reduction with an initial glargine intervention). American Heart Journal 2008;155:
26.e1e26.e13. https://doi.org/10.1016/j.ahj.2007.09.009.
[99] Davies M, D’Alessio D, Fradkin J, Kernan W, Mathieu C, Mingrone G, et al. Manage-
ment of hyperglycemia in type 2 diabetes, 2018. A consensus report by the American
Diabetes Association (ADA) and the European Association for the Study of Diabetes
(EASD). Diabetes Care 2018;41:2669e701. https://doi.org/10.2337/dci18-0033.
[100] Self-monitoring of blood glucose levels for adults with Type 2 diabetes (March 2017).
Diabetes UK; 2017. Available from: https://www.diabetes.org.uk/professionals/position-
statements-reports/diagnosis-ongoing-management-monitoring/self-monitoring-of-
blood-glucose-levels-for-adults-with-type-2-diabetes. [Accessed 31 May 2019].